I’ve been thinking about circles.

Not the conceptual kind — though we’ll get there. The physical kind. The ones visible on a map if you trace the journey of a single generic antibiotic from raw chemical to American pharmacy shelf. Start in a chemical plant in Zhejiang province. Ship key starting materials to a synthesis facility in Gujarat. Convert them to an active pharmaceutical ingredient. Ship the API to a formulation plant — maybe still in India, maybe in a bonded zone elsewhere. Tablet, coat, blister-pack, box. Ship the finished dose to a U.S. distribution center. Dispense.

That circle touches three countries, two oceans, and zero domestic manufacturing steps for the active ingredient. For hundreds of medicines Americans take every day, this is not the exception. It is the architecture.

A new assessment from Business Executives for National Security — BENS, the nonpartisan organization that has partnered with senior national security officials since 1982 — maps this architecture with a specificity that should unsettle anyone who has been following the biomanufacturing reindustrialization conversation. Dave Gryska’s team at BENS just released Generic Drug Manufacturing and Biotechnology Innovation — and it does something I’ve been wanting someone outside government to do for years: it treats the generic pharmaceutical supply chain not as a trade policy problem or a healthcare access problem, but as a national security vulnerability with the same structural characteristics as the semiconductor dependency that launched CHIPS.

I’ve written about the biomanufacturing reindustrialization thesis — the circles and spirals, the learning curves, the factory economics, the builder’s playbook. That piece was about the future: the companies and capital structures that could bring biological manufacturing home. This piece is about the present. Because the BENS report reveals that the system we need to reindustrialize isn’t just underbuilt. It is actively structured against its own repair.

The podcast audio was AI-generated using Google’s NotebookLM.

The Numbers Behind the Dependency

Let me put the scale of the problem in terms that are hard to argue with.

Ninety-one percent of drugs prescribed by American physicians are generics. Ninety percent of those generic prescriptions are supplied by India and China. The FDA estimated that approximately 80% of active pharmaceutical ingredients are manufactured overseas. In 2021, 87% of U.S. generic drug manufacturing facilities were located abroad. The United States directly imports roughly 16% of its APIs from China — but India, which supplies the bulk of finished generic doses to American patients, itself imports 80% of its APIs from China.

This is the cascading dependency that the BENS report traces in detail, and it is the feature I want to hold up to the light. Because it’s not a supply chain. It’s a cascade. A disruption in Chinese chemical manufacturing doesn’t just affect Chinese exports. It ripples through India’s pharmaceutical sector and arrives at American pharmacy counters as a shortage — of antibiotics, of cardiovascular drugs, of the basic medications that chronic disease patients depend on to stay alive.

The data on shortages is the trailing indicator. In 2024, the United States recorded its highest number of drug shortages to date — 323 medications affected. Antibiotics have proven especially vulnerable, experiencing shortages at a rate 42% higher than other generics. These aren’t obscure compounds. They’re the medicines that keep a 68-year-old’s blood pressure managed, that treat a child’s ear infection, that a hospital ICU reaches for when a patient goes septic.

And here’s the number that stopped me: the API Innovation Center examined 40 essential drug molecules — the “Vital 40” — and found that India supplies about 63% of these APIs, Europe 22%, China 8%, and the United States just 5%. Five percent. For the most critical generic medicines in the American formulary, domestic production is a rounding error.

But the 8% figure for China is misleading, and the BENS report is careful about why. An analysis of key starting materials (KSMs) — the precursor reagents that are synthesized into APIs — reveals that China is the sole supplier of KSMs for 679 different APIs. India is the sole KSM supplier for 402. The United States and European Union combined are sole suppliers for 44.

Six hundred and seventy-nine to forty-four.

That ratio is the supply chain expressed as a strategic position. And it tells you that the dependency isn’t just about who fills the last step — the tablet press, the blister pack. It’s about who controls the chemistry underneath. China’s dominance isn’t at the visible end of the supply chain. It’s at the foundation. The KSMs are the geology, and everything above them — APIs, formulations, finished doses — is built on ground that someone else owns.

Why the Circle Won’t Break Itself

In the biomanufacturing reindustrialization thesis, I introduced the idea that biomanufacturing fails in circles and scales in spirals. The circle: no production experience means no competitive yields, which means no capital investment, which means no facilities, which means no production experience. The system is closed. Nothing moves.

The generic drug supply chain is this circle in its most advanced failure state. It didn’t get here by accident. It got here by economic logic operating without strategic constraint — and the BENS report traces the history precisely enough that the mechanism becomes clear.

The 2000 elimination of tariffs on formulated pharmaceuticals — following the 1995 WTO Pharmaceutical Tariff Elimination Agreement — incentivized importing finished drug products. Domestic manufacturing became progressively less competitive. Facilities closed. The Viatris plant in West Virginia — once employing 1,400 workers producing critical generic medications across antibiotics, cardiovascular, and autoimmune therapeutic areas — is one example among many. America’s last factory producing penicillin closed in 2004. Not because the science was lost. Because the economics were untenable.

And here is where the circle logic becomes vicious. Once domestic production stops, the workforce disperses. Once the workforce disperses, restarting production requires not just capital but a labor pool that no longer exists. Once facilities close, the institutional knowledge embedded in those facilities — the process optimizations, the supplier relationships, the regulatory compliance infrastructure — evaporates. You cannot restart what you’ve forgotten how to do. Or rather, you can — but at vastly greater cost and time than maintaining it would have required.

This is why I called it a system designed to prevent its own repair. The cost advantage of foreign production compounds over time. Every year of offshoring means another year of learning curve accumulated abroad and lost domestically. China’s 20,000+ chemical companies, accounting for 40% of global chemical industrial output, aren’t just competitors. They’re the installed base. And by some estimates, it costs 50% less to produce APIs in India versus the United States or Europe, with labor costs in India and China estimated at one-tenth the cost for a Western company.

The circle doesn’t just trap individual companies. It traps the entire sector. The margins on generic drugs are already razor-thin — that’s the whole point of generics. Domestic production faces stringent regulatory compliance, higher labor costs, higher energy costs, and competition from established foreign producers who have been descending the learning curve for decades. No individual company can break this circle alone. The economics won’t allow it.

This is where the BENS report’s framing matters: this is a national security problem requiring a national security response. Not because the market failed in some abstract sense, but because the market optimized for exactly the wrong thing — unit cost — while ignoring systemic fragility. And fragility, in a system that 91% of American prescriptions depend on, is an existential risk wearing the mask of efficiency.

Stockpiles Are Sandbags, Not Levees

The BENS report takes SAPIR — the Strategic Active Pharmaceutical Ingredients Reserve — seriously, and I want to amplify the point because it cuts against a comfortable assumption in Washington.

In August 2025, an executive order directed the Administration for Strategic Preparedness and Response (ASPR) to identify and stockpile APIs for approximately 26 essential medicines. SAPIR is being refilled and expanded. This is a good and necessary step. Stockpiling APIs, which have longer shelf lives than finished drug products, reduces risk at multiple stress points in the supply chain.

But the BENS report says what I’ve been arguing in different language: stockpiling alone is insufficient. It is a passive defense mechanism. It buys time. It does not solve the structural deficit. Without a functioning industrial base to replenish the stockpile, the reserve is a finite resource that will run dry in a prolonged crisis.

Think about what that means operationally. A geopolitical disruption — a Taiwan Strait crisis, an escalation in the South China Sea, a deliberate Chinese export restriction on pharmaceutical precursors — doesn’t resolve in weeks. The scenario that matters isn’t a temporary supply interruption. It’s a sustained one. And a stockpile sized for months faces a crisis measured in years.

The analogy I keep returning to: SAPIR is sa...

Ep 62 - The Generic Drug Trap